ArticleTranslational oncology2026
PUM2 inhibits ferroptosis and enhances oxaliplatin resistance in COAD via the NEDD4L/NRF2 axis.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxaliplatin resistance remains a significant therapeutic challenge in the treatment of colon adenocarcinoma (COAD). In this study, we identified the RNA-binding protein PUM2 as a key driver of oxaliplatin resistance. Bioinformatics analysis revealed that PUM2 was upregulated in tumor tissues, which correlated with poor patient prognosis. Knockdown of PUM2 inhibited cell proliferation and migration and enhanced oxaliplatin sensitivity by promoting ferroptosis. These findings were validated in vivo, where PUM2 knockdown potentiated the anti-tumor efficacy of oxaliplatin in mouse xenograft models. Mechanistically, PUM2 was found to bind to the mRNA of the E3 ubiquitin ligase NEDD4L. Downregulation of NEDD4L reduced the ubiquitination and degradation of the transcription factor NRF2, leading to NRF2 accumulation and inhibiting ferroptosis. Furthermore, combining an NRF2 inhibitor (ML385) with oxaliplatin promoted ferroptosis and suppressed the growth of resistant tumors in vivo. In conclusion, our findings elucidate a novel PUM2/NEDD4L/NRF2 axis that promotes oxaliplatin resistance in COAD by inhibiting ferroptosis, thereby providing a preclinical rationale for future investigation into this pathway to overcome chemoresistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.